Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

Investigational New Drugs

Volumn 28, Issue 6, 2010, Pages 887-894

  Bellati, Filippo ^a,b   Napoletano, Chiara ^b   Ruscito, Ilary ^b   Pastore, Maria ^a   Pernice, Milena ^a   Antonilli, Morena ^a   Nuti, Marianna ^b   Benedetti Panici, Pierluigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ascites; Bevacizumab; Intraperitoneal; Lymphocyte; Ovarian Cancer

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; SORAFENIB; TAXANE DERIVATIVE; TOPOTECAN; TRANSCRIPTION FACTOR FOXP3;

ABDOMINAL DISTENSION; ADJUVANT THERAPY; ADULT; ASCITES; ASCITES TUMOR; BLOATING; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CARCINOMATOSIS; CASE REPORT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EFFECTOR CELL; FEMALE; GASTROINTESTINAL OBSTRUCTION; HUMAN; HYPERTENSION; LIVER DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PARACENTESIS; PRIORITY JOURNAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL; ASCITES; FATAL OUTCOME; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION;

EID: 78549259164     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9351-4     Document Type: Review

References (49)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. LJ Herrinton C Neslund-Dudas SJ Rolnick, et al. 2007 Complications at the end of life in ovarian cancer J Pain Symptom Manage 34 237 43 10.1016/j.jpainsymman.2006.11.011 17606360 (Pubitemid 47371073)
3. AA Ayantunde SL Parsons 2007 Pattern and prognostic factors in patients with malignant ascites: a retrospective study Ann Oncol 18 945 49 1:STN:280:DC%2BD2s3ns1Klsw%3D%3D 10.1093/annonc/mdl499 17298959 (Pubitemid 47054094)
4. PJ Pockros KT Esrason C Nguyen J Duque S Woods 1992 Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics Gastroenterology 103 1302 06 1:STN:280:DyaK3s%2Fht1Ojug%3D%3D 1397889
5. WR Bezwoda L Seymour R Dansey 1989 Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer Cancer 64 1029 33 1:STN:280:DyaL1Mzjs1KhtA%3D%3D 10.1002/1097-0142(19890901)64: 5<1029::AID-CNCR2820640511>3.0.CO;2-# 2758381
6. GC Stuart JG Nation DD Snider P Thunberg 1993 Intraperitoneal interferon in the management of malignant ascites Cancer 71 2027 30 1:STN:280: DyaK3s7osV2qtw%3D%3D 10.1002/1097-0142(19930315)71:6<2027::AID- CNCR2820710617>3.0.CO;2-C 7680276
7. S Sartori I Nielsen D Tassinari L Trevisani V Abbasciano P Malacarne 2001 Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study Oncology 61 192 6 1:CAS:528:DC%2BD3MXntV2mtb4%3D 10.1159/000055374 11574774 (Pubitemid 34701533)
8. DK Armstrong B Bundy L Wenzel, et al. 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 34 43 1:CAS:528: DC%2BD28XhvV2qsQ%3D%3D 10.1056/NEJMoa052985 16394300 (Pubitemid 43048949)
9. RA Adam YG Adam 2004 Malignant ascites: past, present, and future J Am Coll Surg 198 999 1011 10.1016/j.jamcollsurg.2004.01.035 15194082 (Pubitemid 38759851)
10. JD Wright AA Secord TM Numnum, et al. 2008 A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer Int J Gynecol Cancer 18 400 6 1:STN:280: DC%2BD1czhtlWiug%3D%3D 10.1111/j.1525-1438.2007.01027.x 17645510 (Pubitemid 351668295)
11. K El-Shami A Elsaid A El-Kerm 2007 Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites J Clin Oncol 25 9043 (ASCO Meeting Abstracts)
12. CA Hamilton GL Maxwell MR Chernofsky SA Bernstein JH Farley GS Rose 2008 Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer Gynecol Oncol 111 530 32 1:CAS:528:DC%2BD1cXhsVertbbK 10.1016/j.ygyno.2008.04.028 18561992
13. L Zitvogel L Apetoh F Ghiringhelli G Kroemer 2008 Immunological aspects of cancer chemotherapy Nat Rev Immunol 8 59 73 1:CAS:528:DC%2BD2sXhsVKrsLnP 10.1038/nri2216 18097448
14. F Bellati V Visconti C Napoletano, et al. 2009 Immunology of gynecologic neoplasm: analysis of the prognostic significance of the immune status Curr Cancer Drug Targets 9 541 65 1:CAS:528:DC%2BD1MXotlWrsrs%3D 10.2174/ 156800909788486722 19519321
15. GJS Rustin M Quinn T Thigpen, et al. 2004 Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer) J Natl Cancer Inst 96 487 488 15026475
16. SM Rosenberg 2006 Palliation of malignant ascites Gastroenterol Clin North Am 35 189 99 10.1016/j.gtc.2005.12.006 16530120 (Pubitemid 43356596)
17. JS Berek NF Hacker LD Lagasse RK Nieberg RM Elashoff 1983 Survival of patients following secondary cytoreductive surgery in ovarian cancer Obstet Gynecol 61 189 93 1:STN:280:DyaL3s7hs1Sntw%3D%3D 6823360
18. TJ Curiel G Coukos L Zou, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 49 1:CAS:528:DC%2BD2cXntFSkt7g%3D 10.1038/nm1093 15322536 (Pubitemid 39273735)
19. A Bamias V Koutsoukou E Terpos, et al. 2008 Correlation of NK T-like CD3 + CD56+ cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy Gynecol Oncol 108 421 27 1:CAS:528:DC%2BD1cXhtlOqtb0%3D 10.1016/j.ygyno.2007.10.018 18036640
20. JT Tamsma HJ Keizer AE Meinders 2001 Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited Ann Oncol 12 1353 57 1:STN:280:DC%2BD38%2FjsFaltw%3D%3D 10.1023/A:1012504904713 11762804 (Pubitemid 33100238)
21. FJ Schweigert J Raila J Sehouli U Buscher 2004 Accumulation of selected carotenoids, alpha-tocopherol and retinol in human ovarian carcinoma ascitic fluid Ann Nutr Metab 48 241 45 1:CAS:528:DC%2BD2cXotlKgsbw%3D 10.1159/000080457 15331882 (Pubitemid 39382382)
22. A Bamias ML Tsiatas E Kafantari, et al. 2007 Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3 + CD56+ cells with platinum resistance Gynecol Oncol 106 75 81 1:CAS:528:DC%2BD2sXmsFCjsbs%3D 10.1016/j.ygyno.2007.02.029 17433425 (Pubitemid 46898574)
23. RF Meredith DJ Buchsbaum RD Alvarez AF LoBuglio 2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer Clin Cancer Res 13 5643s 5645s 1:CAS:528:DC%2BD2sXhtVCitLvJ 10.1158/1078-0432.CCR-07-0985 17875801 (Pubitemid 47510398)
24. P Wimberger M Heubner H Lindhofer M Jäger R Kimmig S Kasimir-Bauer 2009 Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer Anticancer Res 29 1787 91 1:CAS:528:DC%2BD1MXos1Wntbo%3D 19443405
25. MA Ströhlein R Siegel M Jäger H Lindhofer KW Jauch MM Heiss 2009 Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis J Exp Clin Cancer Res 28 18 10.1186/1756-9966-28- 18 19216794
26. A Grothey MM Sugrue DM Purdie, et al. 2008 Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 5326 34 1:CAS:528:DC%2BD1MXhslCmtw%3D%3D 10.1200/JCO.2008.16.3212 18854571
27. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. CD005392.
28. SA Cannistra UA Matulonis RT Penson, et al. 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180 86 1:CAS:528:DC%2BD2sXhsVKnsbzM 10.1200/JCO.2007.12.0782 18024865 (Pubitemid 350232248)
29. RA Burger MW Sill BJ Monk BE Greer JI Sorosky 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 5165 71 1:CAS:528:DC%2BD2sXhsVKnsb%2FE 10.1200/JCO.2007.11.5345 18024863 (Pubitemid 350237599)
30. S Mabuchi Y Terai K Morishige, et al. 2008 Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model Clin Cancer Res 14 7781 89 1:CAS:528:DC%2BD1cXhsVegtrfP 10.1158/1078-0432.CCR-08-0243 19047105
31. DE Cohn S Valmadre KE Resnick LA Eaton LJ Copeland JM Fowler 2006 Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecol Oncol 102 134 9 1:CAS:528:DC%2BD28XntVSlsbk%3D 10.1016/j.ygyno.2006.01.030 16527339 (Pubitemid 44056263)
32. AA Garcia H Hirte G Fleming, et al. 2008 Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 76 82 1:CAS:528:DC%2BD1cXhsVCrsLc%3D 10.1200/JCO.2007.12.1939 18165643
33. AM Schultheis G Lurje KE Rhodes, et al. 2008 Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab Clin Cancer Res 14 7554 63 1:CAS:528:DC%2BD1cXhtlylur3K 10.1158/1078-0432.CCR-08-0351 19010874
34. NS Azad EM Posadas VE Kwitkowski, et al. 2008 Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 3709 14 1:CAS:528:DC%2BD1cXhtVGjs73J 10.1200/JCO.2007.10.8332 18669456
35. HS Nimeiri AM Oza RJ Morgan, et al. 2008 Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 110 49 55 1:CAS:528: DC%2BD1cXnvVOlu7s%3D 10.1016/j.ygyno.2008.02.009 18423560
36. BJ Monk DC Choi G Pugmire RA Burger 2005 Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecol Oncol 96 902 5 10.1016/j.ygyno.2004.12.001 15721449 (Pubitemid 40255525)
37. BJ Monk E Han CA Josephs-Cowan G Pugmire RA Burger 2006 Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecol Oncol 102 140 4 1:CAS:528:DC%2BD28XntVSlsbY%3D 10.1016/j.ygyno.2006.05.006 16790264 (Pubitemid 44056265)
38. MA Bidus JC Webb JD Seidman GS Rose CR Boice JC Elkas 2006 Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms Gynecol Oncol 102 5 7 1:CAS:528:DC%2BD28XlsFCntrg%3D 10.1016/j.ygyno.2006.03.048 16697451 (Pubitemid 43851062)
39. TM Numnum RP Rocconi J Whitworth MN Barnes 2006 The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma Gynecol Oncol 102 425 8 1:CAS:528:DC%2BD28Xps1WmsL4%3D 10.1016/j.ygyno.2006.05. 018 16797681 (Pubitemid 44353660)
40. N Arora D Tewari C Cowan B Saffari BJ Monk RA Burger 2008 Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma Int J Gynecol Cancer 18 369 72 1:STN:280:DC%2BD1c7nsVamtA%3D%3D 10.1111/j.1525-1438. 2007.01026.x 17624986 (Pubitemid 351365222)
41. JD Wright D Viviano MA Powell, et al. 2006 Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer Gynecol Oncol 103 489 93 1:CAS:528:DC%2BD28XhtFegtbfF 10.1016/j.ygyno.2006.03.023 16647106 (Pubitemid 44602157)
42. JP Kesterson P Mhawech-Fauceglia S Lele 2008 The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report Gynecol Oncol 111 527 29 1:CAS:528:DC%2BD1cXhsVertbbJ 10.1016/j.ygyno.2008.07.015 18710781
43. JP Micha BH Goldstein MA Rettenmaier, et al. 2007 A phase II study of outpatient first-line paclitaxel, carboplatin and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer Int J Gynecol Cancer 17 771 76 1:STN:280:DC%2BD2svhsFGktQ%3D%3D 10.1111/j.1525-1438.2007.00886.x 17343605 (Pubitemid 47063333)
44. LG Presta H Chen SJ O'Connor, et al. 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 99 1:CAS:528: DyaK2sXmslKqtLg%3D 9377574
45. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 35 1:CAS:528:DC%2BD2MXlsVChtLs%3D 10.1016/j.bbrc.2005.05.132 15961063 (Pubitemid 40848295)
46. C Alfaro N Suarez A Gonzalez, et al. 2009 Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes Br J Cancer 100 1111 19 1:CAS:528:DC%2BD1MXktVGktro%3D 10.1038/sj.bjc.6604965 19277038
47. T Osada G Chong R Tansik, et al. 2008 The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients Cancer Immunol Immunother 57 1115 24 1:CAS:528:DC%2BD1cXmt1OisLY%3D 10.1007/s00262-007-0441-x 18193223
48. J Wada H Suzuki R Fuchino, et al. 2009 The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions Anticancer Res 29 881 8 1:CAS:528:DC%2BD1MXltlOqtrs%3D 19414323
49. TE Kute L Savage JR Stehle Jr, et al. 2009 Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing Cancer Immunol Immunother 58 1889 98 10.1007/s00262-009-0700-0